NDAORALTABLET
Approved
Dec 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
CORGARD (nadolol) by Teva is clinical pharmacology nadolol tablets, usp is a nonselective beta-adrenergic receptor blocking agent. Approved for hypertension, migraine. First approved in 1979.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORGARD (nadolol) is a nonselective beta-adrenergic receptor blocking agent approved in 1979 for hypertension, angina, and migraine. It reduces heart rate, cardiac output, and blood pressure by competitively antagonizing beta-1 and beta-2 adrenergic receptors. The drug is characterized by low lipophilicity, minimal CNS penetration, and lack of intrinsic sympathomimetic activity.
$415KPart D
LOE ApproachingDeclining
Minimal commercial scale with only 1,015 annual Part D claims signals a mature, legacy product with limited team expansion opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Nadolol tablets, USP is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic…
Worked on CORGARD at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.